Bothell biotech firm faces delisting from Nasdaq again
November 12, 2020 at 03:12 AM EST
Cocrystal Pharma has failed to maintain the $1 minimum bid price for its common stock for 30 straight business days, in violation of the Nasdaq's listing rule. The company could have up to a year to get back on track.